In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on PAVmed (PAVM – Research Report), with a price target of $4.00.
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight PAVmed’s strategic positioning and potential for growth. The company has shown progress in its subsidiaries, particularly with Lucid Diagnostics and Veris Health. Lucid has made strides in securing Medicare coverage for its EsoGuard test and has seen a promising start with its concierge medicine contracts, indicating potential revenue growth in the latter half of 2025.
Moreover, PAVmed’s extension of its pilot program with the Ohio State University Comprehensive Cancer Center and the securing of financing for Veris Health’s implantable monitoring device underscore the company’s commitment to advancing its medical technology offerings. Despite lowering revenue estimates for 2025 and 2026, the company’s restructuring efforts and strategic initiatives suggest a stable corporate structure poised for future success. The valuation analysis, using both DCF and sum-of-the-parts methods, further supports the Buy rating, as PAVmed appears undervalued relative to its growth prospects.
According to TipRanks, Vendetti is an analyst with an average return of -24.2% and a 24.95% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Daxor, Strata Skin Sciences, and Rockwell Med.